ALISO VIEJO, Calif. and
DUBLIN, Jan. 17, 2017 /PRNewswire-USNewswire/
-- Global Genes® and Horizon Pharma plc (NASDAQ:
HZNP) announced the Horizon Nephropathic Cystinosis Scholarship
(HNCS), an exclusive opportunity for people living with
nephropathic cystinosis to further their education and pursue
opportunities toward long-term career goals. Applicants can
apply for the scholarship by visiting the Global Genes website.
"Global Genes always looks to partner with
organizations that are innovative and doing what is right by the
patient," said Global Genes Founder and CEO, Nicole Boice. "This opportunity with
Horizon Pharma is designed for nephropathic cystinosis patients
that are passionate about learning. We are offering
scholarships to help spark an inspiration through education and
offer patients a chance to develop into leaders within their
communities."
Cystinosis is rare, affecting approximately 500 people in
the United States and 2,000
worldwide.1 Nephropathic or "classic infantile"
cystinosis is the most common and most severe form of the
disease.2,3 New medicines and ongoing research
have improved the long-term prognosis for those living with
nephropathic cystinosis, and people living with the condition can
now plan for living into adulthood and leading productive
lives.4
"In our experience working alongside people living with rare
diseases, we've witnessed an increasing resilience to overcome
adversity and pursue long-term goals," said Rob Metz, senior vice president, patient
advocacy, Horizon Pharma plc. "We hope that these
scholarships will give inspiration to many people living with the
daily challenges of nephropathic cystinosis. Global Genes is
an ideal partner to lead this effort, given the organization's
track record providing connections and resources for the rare
disease community."
Scholarship applications open Wednesday,
January 18, 2017. Applicants must be diagnosed with
nephropathic cystinosis and pursuing educational or career
development support such as community college, university, beauty
school, vocational school, seminars, or special interest courses
such as dance, archery, painting and pottery. The scholarship
is funded through a grant from Horizon Pharma plc with a maximum
scholarship amount of $5,000 and a
minimum of ten scholarships to be awarded. Scholarship
recipients will be selected by an independent board of reviewers
appointed by Global Genes. Learn more and apply at
www.globalgenes.org/HNCS.
About Global Genes® – Allies in Rare Disease
Global
Genes is a leading global rare disease patient advocacy
organization. The mission is to eliminate the challenges of
rare disease, by providing patients with educational tools,
building awareness, providing critical connections and support to
people and resources, and through investment in technologies that
will positively impact affected patients and families.
Recognized worldwide by the Blue Denim Genes Ribbon™, Global
Genes unites experts, advocates and patients of all ages to stand
together in hope for treatments and cures for the estimated 7,000
rare and genetic diseases that impact approximately 30 million
Americans and over 350 million people worldwide.
About Horizon Pharma plc
Horizon Pharma plc is a
biopharmaceutical company focused on improving patients' lives by
identifying, developing, acquiring and commercializing
differentiated and accessible medicines that address unmet medical
needs. Horizon Pharma markets 11 medicines through its
orphan, rheumatology and primary care business units. For
more information, please visit www.horizonpharma.com. Follow
@HZNPplc on Twitter or view careers on the company's LinkedIn
page.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global-genes-and-horizon-pharma-plc-partner-to-offer-nephropathic-cystinosis-scholarships-300391829.html
SOURCE Global Genes